Not available
Quote | TG Therapeutics Inc. (NASDAQ:TGTX)
Last: | $13.78 |
---|---|
Change Percent: | 0.86% |
Open: | $13.87 |
Close: | $13.78 |
High: | $14.015 |
Low: | $13.26 |
Volume: | 3,665,833 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | TG Therapeutics Inc. (NASDAQ:TGTX)
2024-04-18 13:15:50 ET More on TG Therapeutics TG Therapeutics: The Cloud Over Briumvi TG Therapeutics: BRIUMVI Development Could Lead To Great Results TG Therapeutics: Briumvi Growth Story Appears Intact TG Therapeutics jumps after second consecutive quarter...
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at t...
Message Board Posts | TG Therapeutics Inc. (NASDAQ:TGTX)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $TGTX News Article - Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeut | whytestocks | investorshangout | 05/01/2023 8:45:47 PM |
$TGTX just the news we needed | SpaceTimeRift777 | investorshub | 04/30/2023 1:03:53 AM |
The gaining | tw0122 | investorshub | 04/29/2023 10:44:46 PM |
Good read | makinezmoney | investorshub | 04/29/2023 8:13:29 PM |
whytestocks: $TGTX News Article - TG Therapeutics to Host Conference Call on First Quarter 2023 Fina | whytestocks | investorshangout | 04/28/2023 8:40:53 PM |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), announced that it has been awarded a national contract with th...
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at t...
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 A...